UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000001138
Receipt No. R000001369
Scientific Title A randomized controlled trial of intra-arterial infusion of CDDP for hepatocellular carcinoma to prevent intra-hepatic metastasis after curative resection
Date of disclosure of the study information 2008/05/01
Last modified on 2017/04/01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A randomized controlled trial of intra-arterial infusion of CDDP for hepatocellular carcinoma to prevent intra-hepatic metastasis after curative resection
Acronym Efficacy of intra-arterial infusion of CDDP after curative resection of hepatocellular carcinoma
Scientific Title A randomized controlled trial of intra-arterial infusion of CDDP for hepatocellular carcinoma to prevent intra-hepatic metastasis after curative resection
Scientific Title:Acronym Efficacy of intra-arterial infusion of CDDP after curative resection of hepatocellular carcinoma
Region
Japan

Condition
Condition Patients after curative resection of hepatocellular carcinoma
Classification by specialty
Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Hepatocellular carcinoma shows a high recurrent rate of 50 to 70% by 3 years after curative resection. A following treatment for the recurrence is restricted depending on the reduction of hepatic reserve. Therefore, it is critical to establish a preventive means for the recurrence in order to improve the survival and quality of life in patients with hepatocellular carcinoma.
Hepatocellular carcinoma appears to recurrent as de novo or metastasis. It is reported that a successful treatment for a background liver disease significantly reduced de novo cancer development. On the other hand, to date no standard therapy has been established in terms of the prevention of the metastatic disease.
In this trial, cases after curative resection of hepatocellular carcinoma are randomly divided into two groups: a) a group with no additional treatment and b) a group with an intra-arterial infusion of CDDP. At first, the safety issue of the infusion is evaluated. Then, the benefit of the infusion is evaluated on the basis of survival and recurrence-free survival. The effect of the infusion on a way of recurrence is also evaluated.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase I,II

Assessment
Primary outcomes 1. Survival
2. Recurrence-free survival based on the evaluation using computed tomography, magnetic resonance imaging or ultrasound. The evaluation should be conducted every three months and has to be performed with computed tomography or magnetic resonance imaging at least once a 6-months.
3. A way of recurrence
Key secondary outcomes 1. RBC, WBC including differential count, Plt, PT-INR , Bleeding time
2. TP, Alb, AST, ALT, ALP, LDH, gamma-GTP, TBil, BUN, Crt, Na, K, Cl, ChE, T Chol, HbA1c
3. Alpha-fetoprotein, Fucosylated fraction of alpha-fetoprotein, Des-gamma-carboxy prothrombin
4. Urinalysis, Creatinine clearance
5. Background
a. Age, Gender, Performance status, Chest X-ray, ECG
b. HBsAg, anti-HCV, Child-Pugh classification, Indocyanine green retention rate R15 and clearance rate
c. Characteristics of hepatocellular carcinoma: diagnostic modality, size, number, location, extension to hepatic and/or portal vein
d. Alcoholic consumption, Blood transfusion, History of treatment for hepatocellular carcinoma and/or other diseases, History of allergy

Items from #1 to #3 and #4 are evaluated once a month and just before each infusion of CDDP, respectively, while those in #5 are evaluated only at the enrolment.

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control No treatment
Stratification NO
Dynamic allocation YES
Institution consideration Institution is considered as a block.
Blocking YES
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Group A: No additional treatment after curative resection

Interventions/Control_2 Group B: Intra-arterial infusion of CDDP after curative resection

An amount of 65mg/square meter of body surface of CDDP dissolved in saline at the concentration of 100 mg/70 ml is infused targeting the entire residual liver through a catheter inserted into an appropriate artery on 8, 20 and 32 weeks after curative surgical resection of hepatocellular carcinoma. The infusion rate is 3 mg/min, and two weeks earlier or later date is acceptable. When creatinine clearance is less than 90 ml/min or 70 ml/min, the amount of CDDP is reduced to 70% or 50%, respectively. If the previous infusion required additional treatments against adverse effects at Grade 3 of Common Terminology Criteria for Adverse Events v3.0 in terms of WBC, RBC and/or Plt, the amount of CDDP is reduced to 80% in the following infusion.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Performance status is less than 2.
2. Child-Pugh classification is A or B.
3. The following criteria are satisfied.
a. WBC is more than 3,000/microliter.
b. Plt is more than 50,000/microliter.
c. Hb is more than 8.0 g/dl.
d. Total bilirubin is 3.0 g/dl or less.
e. Creatinine clearance adjusted by a body square meter of 1.73 is more than 50 ml/min.
4. There are no other active malignant diseases.
5. No additional anti-cancer treatments have been executed for the last three months, which affect on over the liver.
6. A patient can give informed consent by himself/herself.
Key exclusion criteria 1. The history of severe allergic reaction against iodinated contrast medium and/or platinum-containing drugs.
2. A woman who is pregnant, lactating, or may become pregnant.
3. Hepatocellular carcinoma extended to the first branch of the portal vein or further.
4. Hepatocellular carcinoma extended to the inferior vena cava or further.
5. Dynamic CT or dynamic MRI revealed that hepatocellular carcinoma is solitary and 2 cm or less without vascular invasion.
6. Under interferon therapy.
7. A doctor responsible for the study judged to be inappropriate.
Target sample size 200

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takeshi Suda
Organization Niigata University Graduate School of Medical and Dental Sciences
Division name Department of Gastroenterology and Hepatology
Zip code
Address 1-757 Asahi-Machi, Chuo-Ku, Niigata, Niigata 951-8122
TEL 025-227-2207
Email tspitt@med.niigata-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Tomoyuki Kubota
Organization Niigata Hepatocellular Carcinoma Therapy Study Group
Division name Executive Office
Zip code
Address 1-757 Asahi-Machi, Chuo-Ku, Niigata, Niigata 951-8122
TEL 025-227-2207
Homepage URL
Email t-kubota@med.niigata-u.ac.jp

Sponsor
Institute Niigata Hepatocellular Carcinoma Therapy Study Group
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2008 Year 05 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2008 Year 03 Month 26 Day
Date of IRB
Anticipated trial start date
2008 Year 05 Month 01 Day
Last follow-up date
2015 Year 04 Month 01 Day
Date of closure to data entry
2015 Year 04 Month 01 Day
Date trial data considered complete
2015 Year 04 Month 01 Day
Date analysis concluded
2016 Year 03 Month 01 Day

Other
Other related information

Management information
Registered date
2008 Year 04 Month 28 Day
Last modified on
2017 Year 04 Month 01 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001369

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.